| INTRODUC TI ON
The magnitude of prolactin elevation guides the differential diagnosis of hyperprolactinaemia and typically parallels tumour diameter in prolactinomas. Severe hyperprolactinaemia (>10-fold normal) is almost always due to macroprolactinomas (diameter > 1 cm), pregnancy or breastfeeding. 1 Causes of mild hyperprolactinaemia (<4-fold normal) include microprolactinomas (diameter < 1 cm), dopamine interference (eg stalk compression/transection in the "stalk effect," antipsychotics, metoclopramide), primary hypothyroidism, polycystic ovary syndrome and prolactin co-secretion in acromegaly or Cushing's disease. Mild, transient increases in prolactin may follow stress, pain, coitus, exercise, sleep, meals or seizures.
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| CLINI C AL AUD IT
We performed an audit of 18 patients (12 women, 6 men, age 26-79 years, mean 51 years) with consistently higher serum prolactin on the Roche compared with the Siemens platform ( Table 1 ).
The Siemens Centaur® platform and either the Roche Cobas® or
Roche Modular E170® platforms were employed in each case.
Macroprolactinaemia was excluded by polyethylene glycol (PEG) precipitation in 6/18 patients. PEG precipitation was not performed in the remaining 12 patients as prolactin was normal or near-normal on repeat testing on the Siemens platform (eight patients) or macroprolactinaemia had previously been excluded (four patients).
Clinical confounders were absent in all but three patients. higher) than men (Roche 42% higher), and in patients with prolactinomas (Roche 117% higher) than patients with no final diagnosis of prolactinoma (Roche 57% higher).
The interassay discordance was often clinically significant. For 
| D ISCUSS I ON
Our clinical audit of 18 patients and assay comparison of 40 split samples showed that serum prolactin is consistently overestimated by Roche compared with Siemens, in both absolute values (mIU/L) and in relative values, that is compared with the upper limit of normal. This is relevant to laboratories and to clinicians typically measuring prolactin to investigate menstrual disturbances, low testosterone (in males), infertility or pituitary masses. The potential diagnostic and therapeutic implications of prolactin overestimation are outlined in Table 2 . It is worth also noting the costs of further investigation due to misleadingly high serum prolactin levels, includ- elevations by Roche. The last two patients were being serially followed after surgery for a prolactinoma in one patient and cessation of prolactinoma dopamine agonist treatment in the other patient who had developed disruptive hypersexuality on treatment. These two patients both had gradually increasing serum prolactin levels on the Siemens assay as expected due to their known tumour remnants but their latest prolactin result by Roche created sharp inflections in their trajectories. The sharp inflections were discordant with clinical findings in both cases as both tumour remnants were stable on serial imaging and cabergoline had been restarted in the postoperative patient in the lead up to the latest test. Overall, these informative cases indicated serum prolactin overestimation by Roche.
Our findings of prolactin interassay discordance may be overcome by a higher Roche reference interval as prolactin should always be interpreted relative to the upper limit of normal rather than as an absolute value. Determining new reference intervals will require large numbers of healthy controls and patients with varying degrees of hyperprolactinaemia. In the meantime, clinicians should be aware of the potential for prolactin overestimation and the utility of repeat testing on different platforms. In mild hyperprolactinaemia by the Roche platform with normoprolactinaemia by other platforms, patients may be spared from unnecessary endocrine reviews and MRI studies. In true hyperprolactinaemia, separating patients with mild versus severe hyperprolactinaemia will narrow the diagnostic possibilities. 
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